Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4 + and PDPN + CAFs to clinical outcome.
Gil FriedmanOshrat Levi-GalibovEyal DavidChamutal BornsteinAmir GiladiMaya DadianiAvi MayoCoral HalperinMeirav Pevsner-FischerHagar LavonShimrit MayerReinat NevoYaniv SteinNora Balint-LahatIris BarshackH Raza AliCarlos CaldasEinav Nili-Gal-YamOmer KarinBjørt K KragesteenRuth Scherz-ShouvalPublished in: Nature cancer (2020)
Tumors are supported by cancer-associated fibroblasts (CAFs). CAFs are heterogeneous and carry out distinct cancer-associated functions. Understanding the full repertoire of CAFs and their dynamic changes as tumors evolve could improve the precision of cancer treatment. Here we comprehensively analyze CAFs using index and transcriptional single-cell sorting at several time points along breast tumor progression in mice, uncovering distinct subpopulations. Notably, the transcriptional programs of these subpopulations change over time and in metastases, transitioning from an immunoregulatory program to wound-healing and antigen-presentation programs, indicating that CAFs and their functions are dynamic. Two main CAF subpopulations are also found in human breast tumors, where their ratio is associated with disease outcome across subtypes and is particularly correlated with BRCA mutations in triple-negative breast cancer. These findings indicate that the repertoire of CAF changes over time in breast cancer progression, with direct clinical implications.
Keyphrases
- single cell
- wound healing
- gene expression
- endothelial cells
- transcription factor
- poor prognosis
- metabolic syndrome
- quality improvement
- heat shock
- skeletal muscle
- adipose tissue
- oxidative stress
- breast cancer risk
- high throughput sequencing
- young adults
- induced pluripotent stem cells
- insulin resistance
- heat shock protein